B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

Source Domain: www.openpr.com

The global B-cell maturation antigen (BCMA) targeted therapies market was valued at USD 5.60 billion in 2025 and is projected to reach USD 29.81 billion by 2035, with a CAGR of 18.20% from 2026 to 2035.
The market growth is driven by the rising prevalence of multiple myeloma, improved clinical success rates, and the adoption of next-generation immunotherapies like CAR-T cells and bispecific antibodies.
CAR-T cell therapies dominate the market due to their effectiveness in treating relapsed/refractory multiple myeloma, while bispecific antibodies are gaining traction for their scalability and easier administration.
Artificial intelligence enhances the development of BCMA-targeted therapies, improving therapeutic designs, patient selection, and safety profiles.
North America leads the market with a strong healthcare infrastructure and advanced therapies, while Asia-Pacific is expected to see the fastest growth driven by rising healthcare investments and awareness.

You may have missed